Entinostat induces antitumor immune responses through immune editing of tumor neoantigens is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 0. It has been cited 83 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
American Cancer Society
Grant: RSG-14-219-01-TBG
University Cancer Research Fund
Grant: N/A
National Cancer Institute
Grant: F31 CA247250
National Cancer Institute
Grant: K12CA120780
National Cancer Institute
Grant: R01-CA241810
NCI NIH HHS
Grant: R01 CA241810
NCI NIH HHS
Grant: T32 CA244125
NCI NIH HHS
Grant: R37 CA247676
NCI NIH HHS
Grant: K08 CA248967
NCI NIH HHS
Grant: R01 CA148761
National Institutes of Health
Grant: 5K08CA248967-02
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
National Institutes of Health
Grant: 1K12CA120780-01A1
UNC Oncology Clinical Translational Research Training Program
National Institutes of Health
Grant: 5F31CA247250-02
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy
National Institutes of Health
Grant: 3R01CA241810-04S1
In vivo Assessment of Chemotherapy Remodeling of the Bladder Cancer Immune Microenvironment
FWCI
4.69
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals